NICE has published draft guidance backing two capsule sponge tests, Cytosponge (Medtronic) and EndoSign (Cyted Health), as options for people with persistent reflux and added risk factors for Barrett's oesophagus, and for surveillance of people who already have it. Comments close on 7 December 2026. The case rests on one question for payers: how many endoscopies does the test remove, and how safely?
What the draft covers
The draft applies where an urgent suspected cancer referral is not needed. NICE's committee described the tests as a quicker, less invasive first step than endoscopy, with no sedation, and said wider adoption could reduce the variation in access across England. After a negative result, patients should still be told about symptoms and when to seek further assessment.
The appraisal sits in the HealthTech programme. The NICE project page shows the committee meeting again on 16 December 2026 and final guidance expected on 24 February 2027. The external assessment group is ScHARR at the University of Sheffield. NICE's current guideline recommends endoscopic surveillance, which it describes as invasive and needing sedation, and the project page says the test could reduce the number of endoscopies and so help waiting lists.
The evidence behind the draft
Two bodies of evidence matter: a randomised trial and a non-randomised NHS evaluation. The first is the trial. In a NICE medtech innovation briefing from 2020, a trial in primary care found an adjusted relative risk of 10.6 (95% CI 6.0 to 18.8) for detecting Barrett's oesophagus when Cytosponge was followed by endoscopy, against standard care. That trial enrolled over 13,000 people from 109 GP surgeries, but uptake of the test was around 25.6%. The same briefing pooled 13 studies to a sensitivity of 81% and specificity of 91%.
The second speaks to capacity. A prospective NHS England evaluation in 23 hospitals, published in Alimentary Pharmacology & Therapeutics, put 2,170 patients on waiting lists through the test. In all, 1,694 (78%) were discharged without endoscopy, and none of the 79 patients with a negative test who went on to endoscopy had Barrett's oesophagus.
The paper states its limits: no randomisation, no long-term follow-up, and discharge decisions that varied between sites. The study ran during the COVID-19 pandemic, and dysplasia was not systematically recorded. Some authors disclose patent, licensing or shareholder interests in the Cytosponge test.
The price comparison is not like for like
The only public prices are old. The 2020 briefing gave £280 (excluding VAT) for Cytosponge, covering the device and the laboratory assay, against an estimated £407 for a diagnostic upper gastrointestinal endoscopy with biopsy. The endoscopy figure includes staffing and the sponge figure does not. Because the test is a triage step before endoscopy, the saving depends on the proportion of patients who still need one.
The same briefing lists contraindications, including dysphagia, oesophageal varices, pregnancy and anticoagulant use. Those exclusions shrink the eligible population and need to appear in any budget impact model.
What it means for market access teams
- Model the pathway, not the device. The decision variable is the share of patients discharged without endoscopy. The 78% figure comes from a non-randomised evaluation, so sensitivity analyses should test lower discharge rates and the cost of a missed lesion.
- Prepare for the follow-up question. The committee meets again on 16 December 2026. With no cancers recorded and no long-term follow-up in the NHS evaluation, expect pressure for surveillance data and for a registry or real-world commitment.
- Price against a full endoscopy cost. Staffing sits in the endoscopy tariff but not in the sponge price. Show it explicitly, and include the endoscopies that follow a positive test.
- Plan for variation in uptake. The draft cites uneven access across England. Uptake of 25.6% in the primary care trial shows that offering a test is not the same as completing it.
- Check the laboratory step. Every sample goes to a laboratory for analysis, so budget impact models should include that workload.
Wales has directed its NHS to follow NICE guidance, while Scotland runs a separate process, so a UK launch plan needs more than one route.
To discuss what a NICE HealthTech appraisal means for your evidence plan and pricing, get in touch.